

**Regenerative Medicine Market by Product (Cell Therapy (Autologous, Allogenic), Gene Therapy, Tissue Engineering (Scaffold, Hydrogels), Application (Musculoskeletal, Oncology, Cardiovascular, Ophthalmology, Wound Care), Region - Global Forecast to 2027**

Market Report | 2022-12-19 | 192 pages | MarketsandMarkets

**AVAILABLE LICENSES:**

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

**Report description:**

The regenerative medicine market is projected to reach USD 40.6 Billion by 2027 from USD 12.2 Billion in 2022, at a CAGR of 27.2% during the forecast period. Market growth is driven by the availability of funding and rising investments in R&D, increasing clinical trials for stem cell and CAR-T cell therapies, and rising advancements in tissue-engineered products. However, the high treatment cost of RM therapies and commercialization & regulatory are expected to restrain the market growth during the forecast period.

"By application, the musculoskeletal disorders segment accounted for the largest share of the regenerative medicine market" Based on applications, the regenerative medicine market is segmented into musculoskeletal disorders, wound care, oncology, ocular disorders, dental, and other applications. In 2021, the musculoskeletal disorders segment accounted for the largest market share. This can be attributed to the rising prevalence of orthopedic diseases, the growing geriatric population, the increasing number of stem cell research projects, the growing number of clinical research/trials, and the rich pipeline of stem cell products for treating musculoskeletal disorders.

"Asia Pacific: The fastest-growing region in the regenerative medicine market."

The Asia Pacific market is projected to grow at the highest CAGR during the forecast period, mainly due to increasing research activities in Asian countries, the availability of funding for research, and the growing number of biobanks and research centers are driving the growth of the Asia Pacific regenerative medicine market.

?

"North America: the largest share of the regenerative medicine market"

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

North America accounted for the largest share of the regenerative medicine market. Factors such as the to establishment of stem cell banking, tissue engineering , rise in demand for advanced technology-based treatments like stem cell technology, biologics, tissue engineering, and biomaterials.

The primary interviews conducted for this report can be categorized as follows:

- By Respondent: Supply Side- 80% and Demand Side 20%
- By Designation: C-level - 25%, D-level - 20%, and Others - 55%
- By Region: North America -50%, Europe -20%, Asia-Pacific -20%, Latin America -5%, Middle East and Africa - 5%

#### Major Players

- Novartis AG (Switzerland)
- Biogen (US)
- Sarepta Therapeutics, Inc. (US)
- Gilead Sciences, Inc. (US)
- Amgen, Inc. (US)
- Smith & Nephew plc (UK)
- MEDIPOST Co., Ltd. (South Korea)
- CR Pharmaceuticals Co., Ltd (Japan)
- Takeda Pharmaceutical Company (Japan)
- CORESTEM Inc (South Korea)
- Vericel Corporation (US)
- MIMEDX (US)
- Organogenesis Inc. (US)
- Medtronic plc (US)
- Orthocell Ltd. (Australia)
- Mesoblast Ltd (Australia)
- BioRestorative Therapies (US)
- Pluri Inc, (Israel)
- Tegoscience (South Korea)
- Anterogen Co., Ltd. (South Korea)
- Bluebird Bio (US)
- APAC Biotech (India)
- Shenzhen Sibiono Genetech Co., Ltd. (China)
- Aspect Biosystems (Canada)
- Athersys, Inc. (US)

#### Research Coverage:

This report provides a detailed picture of the regenerative medicine market. It aims at estimating the size and future growth potential of the market across different segments, such as the product, applications, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

#### Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall regenerative medicine market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.

#### Table of Contents:

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

1	INTRODUCTION	29	
1.1	STUDY OBJECTIVES	29	
1.2	MARKET DEFINITION	29	
1.2.1	INCLUSIONS AND EXCLUSIONS	30	
1.3	MARKET SCOPE	30	
	FIGURE 1	REGENERATIVE MEDICINE MARKET SEGMENTATION	30
1.3.1	YEARS CONSIDERED	31	
1.4	CURRENCY CONSIDERED	31	
1.5	LIMITATIONS	31	
1.6	STAKEHOLDERS	32	
1.7	SUMMARY OF CHANGES	32	
2	RESEARCH METHODOLOGY	33	
2.1	RESEARCH DATA	33	
	FIGURE 2	RESEARCH DESIGN	33
2.1.1	SECONDARY DATA	33	
2.1.2	PRIMARY DATA	34	
	FIGURE 3	REGENERATIVE MEDICINE MARKET: BREAKDOWN OF PRIMARIES	35
2.2	MARKET SIZE ESTIMATION	36	
2.2.1	BOTTOM-UP APPROACH	36	
	FIGURE 4	REGENERATIVE MEDICINE MARKET: BOTTOM-UP APPROACH	37
2.2.2	TOP-DOWN APPROACH	37	
	FIGURE 5	REGENERATIVE MEDICINE MARKET: TOP-DOWN APPROACH	37
2.3	GROWTH RATE ASSUMPTIONS	38	
	FIGURE 6	REGENERATIVE MEDICINE MARKET: CAGR PROJECTIONS, 2022-2027	38
	FIGURE 7	REGENERATIVE MEDICINE MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	39
2.4	MARKET BREAKDOWN AND DATA TRIANGULATION	40	
	FIGURE 8	DATA TRIANGULATION METHODOLOGY	40
2.5	PRIMARY INSIGHTS	41	
	FIGURE 9	MARKET VALIDATION FROM PRIMARY EXPERTS	41
2.6	RESEARCH ASSUMPTIONS	41	
2.7	RISK ANALYSIS	42	
3	EXECUTIVE SUMMARY	43	
	FIGURE 10	REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)	43
	FIGURE 11	REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)	44
	FIGURE 12	GEOGRAPHICAL SNAPSHOT OF REGENERATIVE MEDICINE MARKET	45
4	PREMIUM INSIGHTS	46	
4.1	REGENERATIVE MEDICINE MARKET OVERVIEW	46	
	FIGURE 13	AVAILABILITY OF FUNDING FOR RESEARCH AND INCREASING CLINICAL TRIALS IN REGENERATIVE MEDICINE TO DRIVE MARKET	46
4.2	NORTH AMERICA: REGENERATIVE MEDICINE MARKET	47	
	FIGURE 14	CELL THERAPY ACCOUNTED FOR LARGEST MARKET SHARE IN 2021	47
4.3	NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, 2022 VS. 2027 (USD MILLION)	47	
	FIGURE 15	ALLOGENEIC THERAPY TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD	47
5	MARKET OVERVIEW	48	
5.1	INTRODUCTION	48	
5.2	MARKET DYNAMICS	48	
	FIGURE 16	REGENERATIVE MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	48

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.2.1	DRIVERS	49
5.2.1.1	Availability of funding and rising investments in R&D	49
	FIGURE 17	INVESTMENTS IN REGENERATIVE MEDICINE, 2017-2022 (USD BILLION)
	TABLE 1	FUNDING INITIATIVES FROM CORPORATE PARTNERSHIPS IN 2022 (USD MILLION)
	TABLE 2	FUNDING FROM CORPORATE PARTNERSHIPS IN 2021 (USD MILLION)
	FIGURE 18	FUNDRAISING THROUGH PUBLIC OFFERINGS (IPO AND FOLLOW-ONS), 2021 (USD MILLION)
5.2.1.2	Increasing clinical trials for stem cell and CAR-T cell therapies	51
	FIGURE 19	NUMBER OF STEM CELL THERAPY CLINICAL TRIALS (2015?2020)
5.2.1.3	Rising advancements in tissue-engineered products	51
5.2.2	RESTRAINTS	52
5.2.2.1	Issues associated with commercialization and regulatory compliance	52
5.2.2.2	High treatment cost of RM therapies	53
5.2.3	OPPORTUNITIES	53
5.2.3.1	Emerging economies	53
5.2.3.2	Rising cases of organ transplantation	54
5.2.4	CHALLENGES	55
5.2.4.1	Shortage of skilled professionals	55
5.3	PORTER'S FIVE FORCES ANALYSIS	55
	TABLE 3	REGENERATIVE MEDICINE MARKET: PORTER'S FIVE FORCES ANALYSIS
5.3.1	THREAT OF NEW ENTRANTS	55
5.3.2	THREAT OF SUBSTITUTES	56
5.3.3	BARGAINING POWER OF BUYERS	56
5.3.4	BARGAINING POWER OF SUPPLIERS	56
5.3.5	INTENSITY OF COMPETITIVE RIVALRY	56
	?	
5.4	TECHNOLOGY ANALYSIS	57
	FIGURE 20	KEY STEPS IN GENE THERAPY
	TABLE 4	STEM CELL THERAPIES AND GENE THERAPIES
5.5	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	58
	FIGURE 21	REVENUE SHIFT TOWARD REGENERATIVE MEDICINE COMPANIES
5.6	SUPPLY CHAIN ANALYSIS	59
	FIGURE 22	SUPPLY CHAIN ANALYSIS: REGENERATIVE MEDICINE MARKET
5.7	VALUE CHAIN ANALYSIS	60
	FIGURE 23	VALUE CHAIN ANALYSIS: REGENERATIVE MEDICINE MARKET
5.8	ECOSYSTEM ANALYSIS	61
	FIGURE 24	REGENERATIVE MEDICINE MARKET: ECOSYSTEM ANALYSIS
5.9	KEY CONFERENCES AND EVENTS IN 2022	62
5.9.1	REGENERATIVE MEDICINE CONFERENCES IN 2022	62
	TABLE 5	REGENERATIVE MEDICINE CONFERENCES IN 2022
5.10	REGULATORY ANALYSIS	63
5.10.1	FDA APPROVALS	63
5.10.2	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	63
	TABLE 6	NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
	TABLE 7	EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
	TABLE 8	ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
	TABLE 9	REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11	PRICING ANALYSIS	65

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 10 PRICES OF REGENERATIVE MEDICINES 65

5.11.1 REGENERATIVE MEDICINE MARKET: AVERAGE SELLING PRICE OF TREATMENT 66

5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 66

5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 66

FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF REGENERATIVE MEDICINE PRODUCTS 66

5.12.2 BUYING CRITERIA FOR REGENERATIVE MEDICINE PRODUCTS 67

FIGURE 26 KEY BUYING CRITERIA FOR END USERS 67

6 REGENERATIVE MEDICINE MARKET, BY PRODUCT 68

6.1 INTRODUCTION 69

TABLE 11 REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 69

6.2 GENE THERAPY 69

6.2.1 STRONG PRODUCT PIPELINE DUE TO BROADENING APPLICATIONS IN DISEASE TREATMENT TO DRIVE MARKET 69

TABLE 12 REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY REGION, 2020-2027 (USD MILLION) 70

TABLE 13 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2020-2027 (USD MILLION) 70

TABLE 14 EUROPE: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2020-2027 (USD MILLION) 70

TABLE 15 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2020-2027 (USD MILLION) 71

6.3 CELL THERAPY 71

TABLE 16 REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2020-2027 (USD MILLION) 71

TABLE 17 REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY REGION, 2020-2027 (USD MILLION) 72

TABLE 18 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2020-2027 (USD MILLION) 72

TABLE 19 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2020-2027 (USD MILLION) 72

TABLE 20 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2020-2027 (USD MILLION) 73

6.3.1 STEM CELL THERAPY 73

TABLE 21 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020-2027 (USD MILLION) 74

TABLE 22 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY REGION, 2020-2027 (USD MILLION) 74

TABLE 23 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2020-2027 (USD MILLION) 74

TABLE 24 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2020-2027 (USD MILLION) 75

TABLE 25 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2020-2027 (USD MILLION) 75

6.3.1.1 Cell Transplantations 75

6.3.1.1.1 Potential of Allo-SCT in treating AML to drive segment growth 75

TABLE 26 REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY REGION, 2020-2027 (USD MILLION) 76

TABLE 27 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2020-2027 (USD MILLION) 76

TABLE 28 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2020-2027 (USD MILLION) 76

TABLE 29 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2020-2027 (USD MILLION) 77

6.3.1.2 Stem Cell Therapy Products 77

TABLE 30 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY REGION, 2020-2027 (USD MILLION) 78

TABLE 31 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2020-2027 (USD MILLION) 78

TABLE 32 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2020-2027 (USD MILLION) 78

TABLE 33 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2020-2027 (USD MILLION) 79

6.3.1.2.1 Autologous Therapy 79

6.3.1.2.1.1 Low risk of post-treatment complications to support segment growth 79

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 34 REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY REGION, 2020-2027 (USD MILLION) 80

TABLE 35 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2020-2027 (USD MILLION) 80

TABLE 36 EUROPE: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2020-2027 (USD MILLION) 80

TABLE 37 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2020-2027 (USD MILLION) 81

6.3.1.2 Allogeneic Therapy 81

6.3.1.2.1 Favorable scaling up of production processes to support segment growth 81

TABLE 38 REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY REGION, 2020-2027 (USD MILLION) 81

TABLE 39 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2020-2027 (USD MILLION) 82

TABLE 40 EUROPE: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2020-2027 (USD MILLION) 82

TABLE 41 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2020-2027 (USD MILLION) 82

6.3.2 CELL-BASED IMMUNOTHERAPY PRODUCTS 83

6.3.2.1 Adoption of T-cell therapy in cancer treatment to support market growth 83

TABLE 42 REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY PRODUCTS, BY REGION, 2020-2027 (USD MILLION) 83

TABLE 43 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY PRODUCTS, BY COUNTRY, 2020-2027 (USD MILLION) 84

TABLE 44 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY PRODUCTS, BY COUNTRY, 2020-2027 (USD MILLION) 84

TABLE 45 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY PRODUCTS, BY COUNTRY, 2020-2027 (USD MILLION) 84

6.4 TISSUE ENGINEERING (TE) 85

6.4.1 HIGH DEMAND FOR TE PRODUCTS IN DERMATOLOGY AND WOUND CARE APPLICATIONS TO DRIVE MARKET 85

TABLE 46 REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY REGION, 2020-2027 (USD MILLION) 85

TABLE 47 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2020-2027 (USD MILLION) 85

TABLE 48 EUROPE: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2020-2027 (USD MILLION) 86

TABLE 49 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2020-2027 (USD MILLION) 86

?

7 REGENERATIVE MEDICINE MARKET, BY APPLICATION 87

7.1 INTRODUCTION 88

TABLE 50 NUMBER OF CLINICAL TRIALS FOR REGENERATIVE MEDICINE PRODUCTS, BY APPLICATION, 2020 VS. 2021 88

TABLE 51 REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 88

7.2 MUSCULOSKELETAL DISORDERS 89

7.2.1 RISING RESEARCH ON MUSCULOSKELETAL REGENERATION AND PREVALENCE OF ORTHOPEDIC DISORDERS TO DRIVE MARKET 89

TABLE 52 REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2020-2027 (USD MILLION) 90

TABLE 53 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2020-2027 (USD MILLION) 90

TABLE 54 EUROPE: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2020-2027 (USD MILLION) 90

TABLE 55 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2020-2027 (USD MILLION) 91

7.3 ONCOLOGY 91

7.3.1 INCREASING STEM CELL TRANSPLANTS TO DRIVE MARKET 91

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 56 INDICATIVE LIST OF COMMERCIALIZED REGENERATIVE CELL THERAPIES FOR ONCOLOGY APPLICATIONS 92

TABLE 57 REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY REGION, 2020-2027 (USD MILLION) 93

TABLE 58 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2020-2027 (USD MILLION) 94

TABLE 59 EUROPE: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2020-2027 (USD MILLION) 94

TABLE 60 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2020-2027 (USD MILLION) 94

7.4 DERMATOLOGY & WOUND CARE 95

7.4.1 RISING USE OF WOUND CARE BIOLOGICS IN ESTHETICS TO DRIVE MARKET 95

TABLE 61 INDICATIVE LIST OF REGENERATIVE MEDICINE PRODUCTS COMMERCIALIZED FOR TREATMENT OF ACUTE & CHRONIC WOUNDS 95

TABLE 62 REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY REGION, 2020-2027 (USD MILLION) 96

TABLE 63 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2020-2027 (USD MILLION) 96

TABLE 64 EUROPE: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2020-2027 (USD MILLION) 96

TABLE 65 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2020-2027 (USD MILLION) 97

7.5 CARDIOVASCULAR DISEASES 97

7.5.1 INCREASING USE OF MSCS FOR CLINICAL RESEARCH ON IHD TO SUPPORT MARKET GROWTH 97

TABLE 66 REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020-2027 (USD MILLION) 98

TABLE 67 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020-2027 (USD MILLION) 98

TABLE 68 EUROPE: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020-2027 (USD MILLION) 99

TABLE 69 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020-2027 (USD MILLION) 99

7.6 OPHTHALMOLOGY 99

7.6.1 REGENERATION OF EYE TISSUES FOR AMD TO SUPPORT MARKET GROWTH 99

TABLE 70 LIST OF PRODUCTS UNDER PIPELINE FOR REGENERATIVE MEDICINE IN OPHTHALMOLOGY 100

TABLE 71 REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY REGION, 2020-2027 (USD MILLION) 101

TABLE 72 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2020-2027 (USD MILLION) 101

TABLE 73 EUROPE: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2020-2027 (USD MILLION) 101

TABLE 74 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2020-2027 (USD MILLION) 102

7.7 OTHER APPLICATIONS 102

TABLE 75 REGENERATIVE MEDICINE MARKET FOR OTHER APPLICATIONS, BY REGION, 2020-2027 (USD MILLION) 103

TABLE 76 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION) 103

TABLE 77 EUROPE: REGENERATIVE MEDICINE MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION) 103

TABLE 78 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION) 104

8 REGENERATIVE MEDICINE MARKET, BY REGION 105

8.1 INTRODUCTION 106

FIGURE 27 NUMBER OF PLAYERS IN REGENERATIVE MEDICINE MARKET, BY REGION, 2020-2022 106

TABLE 79 NUMBER OF CLINICAL TRIALS FOR REGENERATIVE MEDICINE (2022) 106

TABLE 80 REGENERATIVE MEDICINE MARKET, BY REGION, 2020-2027 (USD MILLION) 107

8.2 NORTH AMERICA 107

FIGURE 28 NORTH AMERICA: REGENERATIVE MEDICINE MARKET SNAPSHOT 108

TABLE 81 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 108

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 82 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 109

TABLE 83 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2020-2027 (USD MILLION) 109

TABLE 84 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020-2027 (USD MILLION) 109

TABLE 85 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2020-2027 (USD MILLION) 110

TABLE 86 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 110

8.2.1 US 110

8.2.1.1 Rising number of pipeline products for regenerative medicine to drive market 110

TABLE 87 PRODUCTS AWAITING APPROVALS IN THE US (2023) 111

TABLE 88 US: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 111

TABLE 89 US: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2020-2027 (USD MILLION) 111

TABLE 90 US: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020-2027 (USD MILLION) 112

TABLE 91 US: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2020-2027 (USD MILLION) 112

TABLE 92 US: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 112

8.2.2 CANADA 113

8.2.2.1 Rising government initiatives for regenerative medicine research to drive market 113

TABLE 93 CANADA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 113

TABLE 94 CANADA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2020-2027 (USD MILLION) 113

TABLE 95 CANADA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020-2027 (USD MILLION) 114

TABLE 96 CANADA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2020-2027 (USD MILLION) 114

TABLE 97 CANADA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 114

8.3 EUROPE 115

TABLE 98 PRODUCTS AWAITING APPROVALS IN EUROPE (2022) 115

TABLE 99 PRODUCTS AWAITING APPROVALS IN EUROPE (2023) 115

TABLE 100 EUROPE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 116

TABLE 101 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2020-2027 (USD MILLION) 116

TABLE 102 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020-2027 (USD MILLION) 116

TABLE 103 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2020-2027 (USD MILLION) 117

TABLE 104 EUROPE: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 117

8.3.1 UK 117

8.3.1.1 Incorporating regenerative medicine into commercial healthcare services under NHS to drive market 117

TABLE 105 UK: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 118

TABLE 106 UK: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2020-2027 (USD MILLION) 118

TABLE 107 UK: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020-2027 (USD MILLION) 118

TABLE 108 UK: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2020-2027 (USD MILLION) 119

TABLE 109 UK: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 119

8.3.2 GERMANY 119

8.3.2.1 Rising focus on clinical research and patent approvals to drive market 119

TABLE 110 GERMANY: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 120

TABLE 111 GERMANY: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2020-2027 (USD MILLION) 120

TABLE 112 GERMANY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020-2027 (USD MILLION) 120

TABLE 113 GERMANY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2020-2027 (USD MILLION) 121

TABLE 114 GERMANY: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 121

8.3.3 FRANCE 121

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

### 8.3.3.1 Structured regulatory framework to drive RM product pipeline 121

TABLE 115 FRANCE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 122

TABLE 116 FRANCE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2020-2027 (USD MILLION) 122

TABLE 117 FRANCE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020-2027 (USD MILLION) 122

TABLE 118 FRANCE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2020-2027 (USD MILLION) 123

TABLE 119 FRANCE: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 123

### 8.3.4 REST OF EUROPE 123

TABLE 120 REST OF EUROPE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 124

TABLE 121 REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2020-2027 (USD MILLION) 124

TABLE 122 REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020-2027 (USD MILLION) 124

TABLE 123 REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2020-2027 (USD MILLION) 125

TABLE 124 REST OF EUROPE: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 125

### 8.4 ASIA PACIFIC 125

FIGURE 29 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET SNAPSHOT 126

TABLE 125 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 127

TABLE 126 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 127

TABLE 127 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2020-2027 (USD MILLION) 127

TABLE 128 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020-2027 (USD MILLION) 128

TABLE 129 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2020-2027 (USD MILLION) 128

TABLE 130 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 128

#### 8.4.1 JAPAN 129

8.4.1.1 Regulatory amendments to pharmaceutical legislation to drive commercialization of therapies 129

TABLE 131 JAPAN: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 129

TABLE 132 JAPAN: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2020-2027 (USD MILLION) 130

TABLE 133 JAPAN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020-2027 (USD MILLION) 130

TABLE 134 JAPAN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2020-2027 (USD MILLION) 130

TABLE 135 JAPAN: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 131

#### 8.4.2 CHINA 131

8.4.2.1 Favorable government support for development of regenerative medicine to drive market 131

TABLE 136 CHINA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 131

TABLE 137 CHINA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2020-2027 (USD MILLION) 132

TABLE 138 CHINA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020-2027 (USD MILLION) 132

TABLE 139 CHINA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2020-2027 (USD MILLION) 132

TABLE 140 CHINA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 133

#### 8.4.3 INDIA 133

8.4.3.1 Introduction of novel therapies for CVD and cancer to support market growth 133

TABLE 141 INDIA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 133

TABLE 142 INDIA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2020-2027 (USD MILLION) 134

TABLE 143 INDIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020-2027 (USD MILLION) 134

TABLE 144 INDIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2020-2027 (USD MILLION) 134

TABLE 145 INDIA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 135

?

#### 8.4.4 SOUTH KOREA 135

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

8.4.4.1 Strong research base and availability of funds to support market growth 135

TABLE 146 SOUTH KOREA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 136

TABLE 147 SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2020-2027 (USD MILLION) 136

TABLE 148 SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020-2027 (USD MILLION) 136

TABLE 149 SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2020-2027 (USD MILLION) 137

TABLE 150 SOUTH KOREA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 137

8.4.5 REST OF ASIA PACIFIC 137

TABLE 151 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 138

TABLE 152 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2020-2027 (USD MILLION) 138

TABLE 153 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020-2027 (USD MILLION) 138

TABLE 154 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020-2027 (USD MILLION) 139

TABLE 155 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 139

8.5 LATIN AMERICA 139

8.5.1 RISING INCIDENCE OF DIABETES AND NEUROLOGICAL DISEASES TO DRIVE ADOPTION OF RM THERAPIES 139

TABLE 156 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 140

TABLE 157 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY CELL THERAPY, 2020-2027 (USD MILLION) 140

TABLE 158 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020-2027 (USD MILLION) 140

TABLE 159 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020-2027 (USD MILLION) 141

TABLE 160 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 141

8.6 MIDDLE EAST & AFRICA 141

8.6.1 INCREASE INCIDENCE OF CHRONIC CONDITIONS TO SUPPORT MARKET GROWTH 141

TABLE 161 MIDDLE EAST & AFRICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 142

TABLE 162 MIDDLE EAST & AFRICA: REGENERATIVE MEDICINE MARKET, BY CELL THERAPY, 2020-2027 (USD MILLION) 142

TABLE 163 MIDDLE EAST & AFRICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020-2027 (USD MILLION) 142

TABLE 164 MIDDLE EAST & AFRICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2020-2027 (USD MILLION) 143

TABLE 165 MIDDLE EAST & AFRICA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 143

9 COMPETITIVE LANDSCAPE 144

9.1 OVERVIEW 144

9.2 STRATEGIES ADOPTED BY KEY PLAYERS 145

FIGURE 30 KEY DEVELOPMENTS IN REGENERATIVE MEDICINE MARKET (JANUARY 2020 -NOVEMBER 2022) 145

9.3 MARKET SHARE ANALYSIS 145

FIGURE 31 REGENERATIVE MEDICINE MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2021) 146

FIGURE 32 REGENERATIVE MEDICINE MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS, BY PRODUCT (2021) 146

9.4 REVENUE SHARE ANALYSIS 147

FIGURE 33 REVENUE ANALYSIS FOR KEY COMPANIES 148

9.5 COMPANY EVALUATION QUADRANT 148

FIGURE 34 REGENERATIVE MEDICINE MARKET: COMPANY EVALUATION MATRIX (2021) 149

9.5.1 STARS 149

9.5.2 EMERGING LEADERS 150

9.5.3 PERVASIVE PLAYERS 150

9.5.4 PARTICIPANTS 150

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

9.6	COMPANY EVALUATION QUADRANT: STARTUPS/SMES	151	
	FIGURE 35	REGENERATIVE MEDICINE MARKET: COMPANY EVALUATION QUADRANT (2021)	151
9.6.1	PROGRESSIVE COMPANIES	151	
9.6.2	STARTING BLOCKS	151	
9.6.3	RESPONSIVE COMPANIES	152	
9.6.4	DYNAMIC COMPANIES	152	
9.7	COMPETITIVE BENCHMARKING	152	
9.7.1	REGENERATIVE MEDICINE MARKET: LIST OF STARTUPS/SMES	152	
	TABLE 166	REGENERATIVE MEDICINE MARKET: LIST OF STARTUPS/SMES	152
9.7.2	REGENERATIVE MEDICINE MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS (STARTUPS/SMES)	153	
	TABLE 167	REGENERATIVE MEDICINE MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS (STARTUPS/SMES)	153
9.8	COMPETITIVE SCENARIO AND TRENDS	154	
	TABLE 168	REGENERATIVE MEDICINE MARKET: DEALS (2020?2022)	154
9.8.1	PRODUCT LAUNCHES AND REGULATORY APPROVALS (2020?2022)	155	
	TABLE 169	REGENERATIVE MEDICINE MARKET: PRODUCT LAUNCHES AND REGULATORY APPROVALS	155
	?		
10	COMPANY PROFILES	156	
	(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*		
10.1	KEY PLAYERS	156	
10.1.1	NOVARTIS AG	156	
	TABLE 170	NOVARTIS AG: BUSINESS OVERVIEW	156
	FIGURE 36	NOVARTIS AG: COMPANY SNAPSHOT (2021)	157
10.1.2	BIOGEN, INC.	159	
	TABLE 171	BIOGEN: BUSINESS OVERVIEW	159
	FIGURE 37	BIOGEN: COMPANY SNAPSHOT (2021)	159
10.1.3	SAREPTA THERAPEUTICS, INC.	161	
	TABLE 172	SAREPTA THERAPEUTICS: BUSINESS OVERVIEW	161
	FIGURE 38	SAREPTA THERAPEUTICS: COMPANY SNAPSHOT (2021)	161
10.1.4	GILEAD SCIENCES, INC.	164	
	TABLE 173	GILEAD SCIENCES INC.: BUSINESS OVERVIEW	164
	FIGURE 39	GILEAD SCIENCES, INC: COMPANY SNAPSHOT (2021)	165
10.1.5	AMGEN, INC.	167	
	TABLE 174	AMGEN INC: BUSINESS OVERVIEW	167
	FIGURE 40	AMGEN, INC: COMPANY SNAPSHOT (2021)	168
10.1.6	SMITH & NEPHEW PLC	170	
	TABLE 175	SMITH & NEPHEW PLC: BUSINESS OVERVIEW	170
	FIGURE 41	SMITH & NEPHEW PLC: COMPANY SNAPSHOT (2021)	171
10.1.7	MEDIPOST CO., LTD.	172	
	TABLE 176	MEDIPOST: BUSINESS OVERVIEW	172
	FIGURE 42	MEDIPOST: COMPANY SNAPSHOT (2021)	172
10.1.8	JCR PHARMACEUTICALS CO., LTD.	174	
	TABLE 177	JCR PHARMACEUTICALS CO., LTD.: BUSINESS OVERVIEW	174
	FIGURE 43	JCR PHARMACEUTICALS CO., LTD: COMPANY SNAPSHOT (2021)	175
10.1.9	TAKEDA PHARMACEUTICAL COMPANY LIMITED	176	
	TABLE 178	TAKEDA PHARMACEUTICAL COMPANY: BUSINESS OVERVIEW	176
	FIGURE 44	TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2021)	177

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.1.10	CORESTEM, INC.	178
TABLE 179	CORESTEM, INC.: BUSINESS OVERVIEW	178
TABLE 180	CORESTEM, INC.: REGULATORY APPROVALS	178
10.1.11	VERICEL CORPORATION	179
TABLE 181	VERICEL CORPORATION: BUSINESS OVERVIEW	179
FIGURE 45	VERICEL CORPORATION: COMPANY SNAPSHOT (2021)	179
10.1.12	MIMEDX	181
TABLE 182	MIMEDX: BUSINESS OVERVIEW	181
FIGURE 46	MIMEDX: COMPANY SNAPSHOT (2021)	181
10.1.13	ORGANOGENESIS, INC.	183
TABLE 183	ORGANOGENESIS INC: BUSINESS OVERVIEW	183
FIGURE 47	ORGANOGENESIS: COMPANY SNAPSHOT (2021)	183
10.1.14	MEDTRONIC PLC	185
TABLE 184	MEDTRONIC PLC: BUSINESS OVERVIEW	185
FIGURE 48	MEDTRONIC PLC: COMPANY SNAPSHOT (2021)	186
10.1.15	ORTHOCELL LTD.	187
TABLE 185	ORTHOCELL: BUSINESS OVERVIEW	187
FIGURE 49	ORTHOCELL LIMITED: COMPANY SNAPSHOT (2021)	187
10.2	OTHER PLAYERS	188
10.2.1	MESOBLAST LTD.	188
10.2.2	BIORESTORATIVE THERAPIES, INC.	188
10.2.3	PLURI INC.	189
10.2.4	TEGOSCIENCE	189
TABLE 186	TEGOSCIENCE: BUSINESS OVERVIEW	189
10.2.5	ANTEROGEN CO., LTD.	190
TABLE 187	ANTEROGEN CO., LTD.: BUSINESS OVERVIEW	190
10.2.6	BLUEBIRD BIO	190
TABLE 188	BLUEBIRD BIO: BUSINESS OVERVIEW	190
10.2.7	STEMPEUTICS RESEARCH	191
TABLE 189	STEMPEUTICS RESEARCH: BUSINESS OVERVIEW	191
10.2.8	SHENZHEN SIBIONO GENETECH CO., LTD.	191
TABLE 190	SHENZHEN SIBIONO GENETECH CO., LTD.: BUSINESS OVERVIEW	191
10.2.9	ASPECT BIOSYSTEMS	192
TABLE 191	ASPECT BIOSYSTEMS: BUSINESS OVERVIEW	192
10.2.10	ATHERSYS, INC.	192
TABLE 192	ATHERSYS, INC.: BUSINESS OVERVIEW	192

\*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

11	APPENDIX	193
11.1	DISCUSSION GUIDE	193
11.2	KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL	196
11.3	CUSTOMIZATION OPTIONS	198
11.4	RELATED REPORTS	198
11.5	AUTHOR DETAILS	199

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

**Regenerative Medicine Market by Product (Cell Therapy (Autologous, Allogenic), Gene Therapy, Tissue Engineering (Scaffold, Hydrogels), Application (Musculoskeletal, Oncology, Cardiovascular, Ophthalmology, Wound Care), Region - Global Forecast to 2027**

Market Report | 2022-12-19 | 192 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

**ORDER FORM:**

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com

Zip Code\*

Country\*

Date

2026-06-09

Signature

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

[www.scotts-international.com](http://www.scotts-international.com)